Biopeople

New at the business helm

New at the business helm

23.03.2015 - Business authority Paul Wallace joins the helm of Cambridge-based MISSION Therapeutics’ as Chief Business Officer. MISSION specialises on the discovery and development of elucidating and targeting the ubiquitin pathway to treat cancers and other diseases. Among other projects, Paul will formulate its future business strategy in the exploration of development partnerships.

Paul’s abundance of experience in drug discovery development spans almost 20 years. Most recently, he was Executive Vice President and Head of Business Development at Medivir AB, where he was also a member of the Executive Management Team responsible for strategic and operational leadership, R&D portfolio management and investment planning. Prior to his roles in business development, Paul enjoyed a career in pharmaceutical research and undertook his PhD and post-doctoral studies at the University of Cambridge.

“With MISSION currently embarking on the preclinical development of its lead molecules, Paul’s extensive business development experience will be invaluable in helping us find the right strategic partnerships to fully realise the potential of these assets. Our core focus is cancer, but our platform discovery approach has yielded highly promising molecules for other indications, such as Parkinson’s disease. We see partnering as an attractive option for taking these non-core projects forward,” commented Anker Lundemose, MISSION Chief Executive Officer.

http://www.european-biotechnology-news.com/people/bio-people/2015/paul-wallace.html

02.09.2014 The former Chair of the Supervisory Board of Dutch clinical-stage immunotherapy company ISA Pharmaceuticals B.V., Ronald Loggers will in the future head the company's daily business activities as CEO.

© ISA Pharmaceuticals

Once Managing Director of ISA’s investor Multi­fund B.V., Loggers took over as acting CEO in June. The new Chief Executive, who holds an MBA from INSEAD and an M.Sc. in Chemical Engineering from the Delft University of Technology, has served on boards in the past, and was Managing Director at Pearle Benelux. Prior to that, he worked for McKinsey & Company and Fokker Aircraft.

28.08.2014 Long-time CEO of Santen Inc. Adrienne Graves has joined the Board of Directors at French ophthalmic company Nicox S.A.

© Nicox

In tandem with Luzi von Bidder and Les Kaplan, who are also freshly appointed to the Board, Graves will be replacing Vaughn Kailian and Vince Anido, who are both stepping down. Before taking on duties as President and CEO at Santen – the US arm of Japan's largest ophthalmic pharmaceutical company – Graves spent nine years with Alcon Laboratories, where her roles included that of Director of International Ophthal­mology. She currently serves as Director on several corporate boards, among them Akorn Inc., TearLab Corporation, Aerpio, Encore Vision and Envisia Therapeutic.

25.08.2014 Gene and cell therapy company Oxford Biomedica plc has appointed Paul Blake as Chief Development Officer.

© Oxford Biomedica

Most recently, Paul was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a Canada-based biopharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014. Paul was a Member of the Board at Memory Pharmaceutical, Inc. and founding Board member of Protez Pharmaceuticals, which were later acquired by Roche and Novartis, respectively. He was also Director of ViaCell and held senior management positions at Cephalon Inc. He is a fellow of the Royal College of Physicians, a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and also a fellow of the American College of Clinical Pharmacology.

Effective September 1st, Blake will take over responsibility for the clinical development of Oxford Biomedica’s therapy pipeline. Blake will also remain a member of the company’s board, which he joined in early 2010.

22.08.2014 Alex Blanchard has taken over the lead for the Microscopy Group of Reading Scientific Services Ltd (RSSL), a analytical service provider to the global food, drink, pharmaceutical and healthcare sectors.

© RSSL

Blanchard was previously Group Analytical and Microbiology Manager at Rentokil Initial. Prior to that he led Procter & Gamble's European Microbiology Department, where he oversaw microbiology risk management for a wide range of products. He was also Global Microbiology Leader for Visualisation and Demos using the latest microscopy capabilities.

As RSSL's Senior Group Leader of Microscopy, Blanchard will head the section using microscopy techniques for projects in new product development.

21.08.2014 Swedish pharmaceutical company Medivir has a new president and CEO: board member Niklas Prager is succeeding Maris Hartmanis effective September 1st.

© Medivir

Prager has long experience of senior executive positions in trade and industry - both as CEO and as board member. He is currently chairman of the board of Qbtech AB and a member of the board of Egain Group AB. Before that, he was chairman of the boards of Biophausia AB, Envirotainer AB and Michael Berglund Search Group AB. He has also served as the CEO of Pfizer AB, Envirotainer AB and Qbtech AB. Stockholm-based Medivir expects a strong contribution to the company's strategic business development and commercialisation of its product portfolio. Prager commented: "An update of Medivir’s strategic plan is the number one priority, and work on this is already well under way."

18.08.2014 Adrian Percy has taken over the position of Global Head of Research and Development at Bayer Cropscience and is also the newest member of the Excecutive Committee.

© Bayer Cropscience

Most recently, Percy was responsible for for regulatory affairs activities at Bayer Cropscience as Senior Vice President of Global Regulatory Affairs. Before that, he held numerous positions in the Research and Development departments of the German company and its legacy companies in France, Germany and the USA. He grew up and studied in the United Kingdom earning a Bachelor’s degree in Pharmacology at the University of Liverpool, a Master’s degree in Toxicology and then a doctorate in Biochemistry at the University of Birmingham. Percy succeeds David Nicholson, who has left the company.

14.08.2014 Matthew Pauls is taking over the leadership for Swedish biopharmaceutical company Cortendo AB. With his extensive pharma background and experience in commercial operations, Pauls aims to orient Cortendo toward product commercialisation.

Cortendo AB

Once Pauls has taken over the new role of president and CEO, erstwhile CEO Joseph Reiser will assume the position of chairman of the board. Current chairman Eigil Stray Spetalen will step down to assume a regular board position.

Before joining Cortendo, Pauls was Chief Commercial Officer of US biopharmaceutical company Insmed, Inc, and before that, he worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations. Pauls also held positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson & Johnson in various US and global commercial roles. Mr. Pauls holds BS and MBA degrees from Central Michigan University and a JD from Michigan State University College of Law.

07.08.2014 John P. Donoghue is taking over the management of the Geneva Wyss Center for Bio-and Neuro-engineering at Campus Biotech.

campus biotech

The internationally recognised neuroscientist was also appointed adjunct professor at the École Polytechnique Fédérale de Lausanne (EPFL) and visiting professor at the University of Geneva. Donoghue is the founder of Brown University’s Institute for Brain Science in Rhode Island, USA, and works as a professor of neuroscience and engineering at Brown University. He also holds the Henry Merritt Wriston chair. He will take a one year sabbatical from Brown in 2015 during which he will be devoted to his position as Head of the Wyss Center.

Donoghue is among the founding fathers of neuroprosthetics - the merger between neuroscience and cybernetics. He is best known for having developed innovative brain-computer interfaces for people with paralysis.

11.08.2014 Sir Alec Jeffreys has been awarded the Royal Society’s Copley Medal. The British geneticist received the medal for his pioneering work on variation and mutation in the human genome.

Jane Gitschier, PLoS Genetics

Jeffreys is well known for his 1984 discovery of a method to show the variation between individuals’ DNA, a technique which became known as genetic fingerprinting.  He made the discovery in his lab at the University of Leicester after looking at an X-ray image of the DNA of the different members of his lab technician’s family. Genetic fingerprinting has since been used to resolve issues of identity and kinship, becoming a formative method used in modern forensic science. Jeffreys continued working with this method, further refining it towards DNA profiling. “Sir Alec’s work has transformed our understanding of human genetics“, said Sir Paul Nurse, President of the Royal Society.

The Royal Society awards the Copley medal since 1731, making it the scientific prize believed to be the oldest in the world. It is awarded for outstanding achievements in scientific research. Before Jeffreys, scientists such as Charles Darwin, Michael Faraday, Albert Einstein and Stephen Hawking have been awarded.

04.08.2014 Former Merck & Co. president for Europe and Canada Bruno Strigini has been appointed president of Novartis Oncology.

Novartis Oncology

Right off the bat, Strigini’s career started off internationally, with an MBA from Swiss IMD, a doctorate degree in pharmacy from the French University of Montpellier, and a master's degree in microbiology from UK’s Heriot-Watt University. Since then, he has worked in pharmaceuticals, animal health, OTC and vaccines for 25 years. Strigini has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham. Previous roles have included President of International Operations, President of Japan and Asia-Pacific, and Senior Vice-President and Head of Global Marketing & Business Development, as well as Managing Director positions in New Zealand, the UK and Spain.

His expertise stretches across diverse geographies, including both mature and emerging markets. He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France.

Vorherige Seite5/24Nächste Seite

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Product of the week

Products

Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.28 EUR52.38%
  • THERAMETRICS0.08 CHF14.29%
  • WILEX2.96 EUR1.37%

FLOP

  • MOLOGEN5.68 EUR-28.01%
  • MORPHOSYS54.71 EUR-22.45%
  • MEDIGENE11.65 EUR-13.70%

TOP

  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%

TOP

  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR230.7%

FLOP

  • CYTOS1.40 CHF-53.0%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 27.03.2015

Current issue

All issues